CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth

References

• Kuppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clinical Invest 2012; 122:3439-47; PMID:23023715; http://dx.doi.org/10.1172/JCI61245
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Celegato M, Casagrande N. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance. Canc Lett 2015. PMID:26474544; http://dx.doi.org/10.1016/j.canlet.2015.10.007
   PubMed Web of Science ®Google Scholar
• Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A, Hessel A, Tipsword M, Williams A, Mirtsos C et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999; 189:1939-46; PMID:10377189; http://dx.doi.org/10.1084/jem.189.12.1939
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U, Patterson B, Snow BE, Mak TW. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001; 97:250-5; PMID:11133768; http://dx.doi.org/10.1182/blood.V97.1.250
   PubMed Web of Science ®Google Scholar
• Ullrich K, Blumenthal-Barby F, Lamprecht B, Kochert K, Lenze D, Hummel M, Mathas S, Dörken B, Janz M. The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells. Leukemia 2015; 29:1213-8; PMID:25486870; http://dx.doi.org/10.1038/leu.2014.345
   PubMed Web of Science ®Google Scholar
• Ho WT, Pang WL, Chong SM, Castella A, Al-Salam S, Tan TE, Moh MC, Koh LK, Gan SU, Cheng CK et al. Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Canc Res 2013; 73:652-61; PMID:23204227; http://dx.doi.org/10.1158/0008-5472.CAN-12-3849
   PubMed Web of Science ®Google Scholar
• Anderson MW, Zhao S, Freud AG, Czerwinski DK, Kohrt H, Alizadeh AA, Houot R, Azambuja D, Biasoli I, Morais JC et al. CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Path 2012; 181:795-803; PMID:22901750; http://dx.doi.org/10.1016/j.ajpath.2012.05.015
   PubMed Web of Science ®Google Scholar
• Wang S, Chen L. Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. Curr Top Microbiol Immunol 2011; 344:245-67; PMID:20582531; http://dx.doi.org/10.1007/82_2010_81
   PubMed Web of Science ®Google Scholar
• Thum E, Shao Z, Schwarz H. CD137, implications in immunity and potential for therapy. Front Biosci 2009; 14:4173-88; PMID:19273343; http://dx.doi.org/10.2741/3521
   PubMed Web of Science ®Google Scholar
• Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009; 229:192-215; PMID:19426223; http://dx.doi.org/10.1111/j.1600-065X.2009.00765.x
   PubMed Web of Science ®Google Scholar
• Dharmadhikari B, Wu M, Abdullah S, Rajendran S, Ishak D, Nickles E et al. CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. Oncoimmunol 2015. 5(4); page e1113367; PMID:27141396; http://dx.doi.org/10.1080/2162402X.2015.1113367
   PubMedGoogle Scholar
• Michel J, Langstein J, Hofstadter F, Schwarz H. A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol 1998; 28:290-5; PMID:9485208; http://dx.doi.org/10.1002/(SICI)1521-4141(199801)28:01%3c290::AID-IMMU290%3e3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Shao Z, Sun F, Koh DR, Schwarz H. Characterisation of soluble murine CD137 and its association with systemic lupus. Mol Immunol 2008; 45:3990-9; PMID:18640726; http://dx.doi.org/10.1016/j.molimm.2008.05.028
   PubMed Web of Science ®Google Scholar
• Setareh M, Schwarz H, Lotz M. A mRNA variant encoding a soluble form of 4-1BB, a member of the murine NGF/TNF receptor family. Gene 1995; 164:311-5; PMID:7590349; http://dx.doi.org/10.1016/0378-1119(95)00349-B
   PubMed Web of Science ®Google Scholar
• Furtner M, Straub RH, Kruger S, Schwarz H. Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia. Leukemia 2005; 19:883-5; PMID:15744355; http://dx.doi.org/10.1038/sj.leu.2403675
   PubMed Web of Science ®Google Scholar
• Caumartin J, Lemaoult J, Carosella ED. Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity. Transpl Immunol 2006; 17:20-2; PMID:17157208; http://dx.doi.org/10.1016/j.trim.2006.09.032
   PubMed Web of Science ®Google Scholar
• Pang WL, Ho WT, Schwarz H. Ectopic CD137 expression facilitates the escape of Hodgkin and Reed-Sternberg cells from immunosurveillance. Oncoimmunol 2013; 2:e23441; PMID:23734307; http://dx.doi.org/10.4161/onci.23441
   PubMed Web of Science ®Google Scholar
• Shao Z, Harfuddin Z, Pang WL, Nickles E, Koh LK, Schwarz H. Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation. J Leukoc Biol 2015; PMID:25765680; http://dx.doi.org/10.1189/jlb.3A0213-079RRR
   PubMed Web of Science ®Google Scholar
• Natoli A, Lupertz R, Merz C, Muller WW, Kohler R, Krammer PH, Li-Weber M. Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int J Canc 2013; 133:1945-54; PMID:23553437; http://dx.doi.org/10.1002/ijc.28189
   PubMed Web of Science ®Google Scholar
• Celegato M, Borghese C, Casagrande N, Mongiat M, Kahle XU, Paulitti A, Spina M, Colombatti A, Aldinucci D et al. Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. Blood 2015; 126:1394-7; PMID:26228484; http://dx.doi.org/10.1182/blood-2015-07-660365
   PubMed Web of Science ®Google Scholar
• Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Canc Immunol Immunother 2004; 53:79-85; PMID:14610620; http://dx.doi.org/10.1007/s00262-003-0445-0
   PubMed Web of Science ®Google Scholar
• Hsu SM, Xie SS, Hsu PL, Waldron JA, Jr. Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease. Am J Pathol 1992; 141:129-38; PMID:1632458
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Kapp U, Mak TW. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymph 2002; 43:1203-10; PMID:12152987; http://dx.doi.org/10.1080/10428190290026259
   PubMed Web of Science ®Google Scholar
• Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymph 1993; 9:1-25; PMID:7682880; http://dx.doi.org/10.3109/10428199309148499
   PubMed Web of Science ®Google Scholar
• Shao Z, Schwarz H. CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol 2011; 89:21-9; PMID:20643812; http://dx.doi.org/10.1189/jlb.0510315
   PubMed Web of Science ®Google Scholar
• Langstein J, Michel J, Fritsche J, Kreutz M, Andreesen R, Schwarz H. CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol 1998; 160:2488-94; PMID:9498794
   PubMed Web of Science ®Google Scholar
• Oshima Y, Puri RK. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist. Cell Immunol 2001; 211:37-42; PMID:11585386; http://dx.doi.org/10.1006/cimm.2001.1828
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Kapp U, Mak TW. Interleukin 13: a growth factor in hodgkin lymphoma. International archives of allergy and immunology 2001; 126:267-76; PMID:11815733; http://dx.doi.org/10.1159/000049523
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Canc Res 2015; 21:3113-20; PMID:25908780; http://dx.doi.org/10.1158/1078-0432.CCR-15-0263
   PubMed Web of Science ®Google Scholar